Screener
CRISPR Therapeutics CRSP Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Restricted cash | 7,629 | 7,629 |
| Operating lease assets | 128,671 | 131,724 |
| Other non-current assets | 28,983 | 24,368 |
| Total assets | $2,725,820 | $2,265,243 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $13,647 | $11,138 |
| Accrued expenses | 74,932 | 89,407 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's total assets?
- CRISPR Therapeutics (CRSP) reported total assets of $2.73B in Q1 2026.
- How has CRISPR Therapeutics's total assets changed year-over-year?
- CRISPR Therapeutics's total assets increased by 25.8% year-over-year, from $2.17B to $2.73B.
- What is the long-term trend for CRISPR Therapeutics's total assets?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's total assets has grown at a 4.4% compound annual growth rate (CAGR), from $1.83B to $2.27B.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about CRISPR Therapeutics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude